comprehensive -WSS

comprehensive

author：knowledge 2025-09-30 13:14:12 - browse：42

A doctor climbs up a red ladder to a vine shaped like a DNA — biotech coverage from STAT — Adobe

Every morning, Victoria Rasberry gets up before 6 a.m., walks to the bedroom down the hall, and helps her 8-year-old daughter Addi slide into a set of contraptions that squeeze and suck out the thick mucus constantly threatening to choke her airways closed. She feeds Addi breakfast through a stomach tube and makes sure she has the right mix of the 28 different medications required to keep her free of pain, infections, and seizures. At some point, Rasberry’s five other children will wake up and start to get ready for school, including her youngest, Oliver. At 3-and-a-half years old, he’s a typical toddler — always running and giggling and getting into things. You would never know that he and Addi were born with the same mutation lurking in their DNA, a genetic glitch that causes a fatal neurodegenerative disease called metachromatic leukodystrophy, or MLD.

“When Addi was this age she had lost the ability to speak and was already using a ventilator to sleep at night,” Rasberry said. “It’s amazing to see how well Ollie is doing in comparison. And it’s all because of the gene therapy.”

Three years ago, when Ollie was just 6 months old, he and Victoria traveled from their home in Texas to Milan, to receive a gene therapy treatment that adds a healthy version of the defective gene into patients’ own stem cells. At the time, traveling abroad for the therapy, which is manufactured by Orchard Therapeutics and was approved in Europe in 2021, was the only option for families stricken by MLD. But soon it will be available in the U.S., too.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Intellia reports positive results for its CRISPR

WSS

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

After affirmative action ruling, medical educators look to 'holistic review'

The Pandemic Treaty must support building strong health systems

The cancer drug shortage isn’t new — and neither are the solutions

ChatGPT in medicine: STAT answers readers' burning questions

Letters to First Opinion on caregivers, digital health, and more

knowledge

comprehensive

leisure time

Hepatitis C has a cure — but many Americans still lack access to it

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Sports medicine is finally prioritizing gender equality

BMI, flaws aside, is found to be useful estimate of body fat in youth

After affirmative action ruling, medical educators look to 'holistic review'

Psychedelics group wrestles with new pharma identity

DIEP, the 'gold standard' of breast reconstruction, is under threat

Walensky prepares to leave CDC — and Congress — behind

Dobbs anniversary: the lost opportunity of abortion as health care

Cord blood banking comes at a high cost to babies

explore

Letters to First Opinion on caregivers, digital health, and more

ASCO: AstraZeneca says CAR

See how much Covid

Ultragenyx gene therapy for rare liver ailment succeeds in late

Drug repurposing or repositioning? The language matters

How to save PrEP access — and even expand it

hotspot

knowledge

focus

knowledge